Effective Administration Route for the Deleted Form of Hepatocyte Growth Factor To Exert Its Pharmacological Effects
- 1 January 1999
- journal article
- research article
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 88 (1) , 131-135
- https://doi.org/10.1021/js9800432
Abstract
The pharmacokinetics and the pharmacological effects of the deleted form of hepatocyte growth factor (dHGF) after intravenous (iv), subcutaneous (sc), or intramuscular (im) administration (0.25 and 2. 5 mg/kg) were studied in rats. After single iv administration (2.5 mg/kg), dHGF in serum rapidly decreased (alpha- and beta-phase half-life: 3.2 and 26.5 min, respectively). Two to four hours after single sc or im administration (2.5 mg/kg), the serum level of dHGF reached a maximum and then gradually declined (half-life: 2.7 h). The serum levels were not changed by repetitive iv administration, but were dramatically decreased by repetitive sc or im administration. Liver weight and serum levels of total protein, albumin, and HDL-cholesterol were significantly increased by iv administration of dHGF (twice daily for 4 days at 0.25 mg/kg). Sc or im administration of dHGF did not increase these parameters at the same dose, but did significantly at 2.5 mg/kg. These observations suggest that iv administration is the most effective in exerting the pharmacological effects of dHGF among three administration routes. dHGF after iv administration was distributed mainly and rapidly into liver (53.6% of the injected dHGF within 5 min) and was sustained at a higher level in the liver than in plasma. In infusion (0.5 mg/kg/3 h), dHGF level in plasma and liver reached a steady-state 15 and 60 min after starting the infusion, respectively. The steady-state level of dHGF was 7- to 9-fold higher in liver than in plasma, and the higher level in liver was sustained beyond the steady-state.Keywords
This publication has 22 references indexed in Scilit:
- Hepatocyte Growth Factor and Its Variant with a Deletion of Five Amino Acids Are Distinguishable in Their Biological Activity and Tertiary StructureBiochemical and Biophysical Research Communications, 1994
- Deletion of kringle domains or the N-terminal hairpin structure in hepatocyte growth factor results in marked decreases in related biological activitiesBiochemical and Biophysical Research Communications, 1991
- Tumor cytotoxic factor/hepatocyte growth factor from human fibroblasts: Cloning of its cDNA, purification and characterization of recombinant proteinBiochemical and Biophysical Research Communications, 1991
- ELISA for F-TCF (human hepatocyte growth factor/hHGF)/fibroblast-derived tumor cytotoxic factor antigen employing monoclonal antibodies and its application to patients with liver diseasesGastroenterologia Japonica, 1991
- Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assayHepatology, 1991
- Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factorBiochemical and Biophysical Research Communications, 1990
- Molecular cloning and expression of human hepatocyte growth factorNature, 1989
- Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factorBiochemical and Biophysical Research Communications, 1989
- Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure.Journal of Clinical Investigation, 1988
- Purification and subunit structure of hepatocyte growth factor from rat plateletsFEBS Letters, 1987